Quantcast

Taro Provides Results for September 30, 2020

HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2020.

Quarter ended September 30, 2020 Highlights ─ compared to September 30, 2019

  • Net sales of $142.8 million decreased $18.0 million.
  • Gross profit of $81.6 million (57.1% of net sales compared to 63.2%) decreased $20.0 million.
  • Research and development (“R&D”) expenses of $16.6 million increased $1.0 million.
  • (Read more…)

  • Selling, marketing, general and administrative expenses (“SG&A”) of $24.1 million increased slightly.
  • Operating income of $41.0 million (28.7% of net sales compared to 38.9%) decreased $21.6 million.
  • Interest and other financial income of $5.7 million decreased $3.2 million, reflecting the lower global interest rate environment.
  • Tax expense of $3.6 million decreased $12.7 million; with the effective tax rate of 7.4% compared to 22.4%.
  • Net income attributable to Taro was $45.1 million compared to $56.2 million, an $11.1 million decrease, resulting in diluted earnings per share of $1.18 compared to $1.46.

Six Months ended September 30, 2020 Highlights ─ compared to September 30, 2019

  • Net sales of $260.5 million compared to $322.1 million decreased $61.7 million.
  • Gross profit of $146.5 million (56.3% of net sales compared to 63.1%) decreased $56.8 million.
  • R&D expenses of $29.5 million increased slightly.
  • SG&A of $46.3 million increased $3.0 million.
  • Settlements and loss contingencies of $478.9 million reflect the one-time settlement charge (taken in the first quarter) which consists of $418.9 million related to the global resolution of the Department of Justice (“DOJ”) investigations into the U.S. generic pharmaceutical industry and an additional provision of $60.0 million related to ongoing multi-jurisdiction civil antitrust matters; however, there can be no assurance as to the ultimate outcome.
  • Operating (loss) of $(408.2) million compared to operating income of $131.1 million. Excluding the settlement and loss contingencies charges, operating income was $70.7 million, a decrease of $60.4 million, and as a percentage of net sales was 27.2% compared to 40.7%.
  • Interest and other financial income of $13.0 million decreased $5.5 million.
  • FX income of $0.8 million compared to $7.9 million in 2019 ─an unfavorable impact of $7.1 million.
  • Tax expense of $12.4 million decreased $24.2 million. Excluding the impact from the settlement and loss contingencies charges, the effective tax rate was 14.4% compared to 23.1%.
  • Net (loss) attributable to Taro was $(389.8) million compared to net income of $122.4 million, resulting in diluted (loss) earnings per share of $(10.19) compared to $3.17. Excluding the impact from the settlement and loss contingencies charges, net income was $74.2 million; resulting in diluted earnings per share of $1.94.

Cash Flow and Balance Sheet Highlights

  • Cash flow (used in) operations for the six months ended September 30, 2020, was $(48.1) million. Excluding the impact from the settlement and loss contingencies charges, cash flow provided by operations was $54.7 million compared to $123.4 million for the six months ended September 30, 2019.
  • As of September 30, 2020, cash and cash equivalents and marketable securities (both short and long-term), decreased $49.6 million to $1.5 billion from March 31, 2020; due to a partial payment made as a result of the DOJ settlement announced in July.

Mr. Uday Baldota, Taro’s CEO stated, “Performance this quarter is a result of improving sales across all our business segments over first quarter, even while continuing to be negatively impacted by the pandemic. Our teams have worked tirelessly to serve our customers and patients through these tumultuous times as evidenced by regular product launches and steady market shares. With the recent surge in COVID-19 in our key geographies, and the resulting mitigation steps by respective authorities, we are cautious about the impact on our business for the rest of the year. However, our longer term commitment to enrich our product portfolio, organically or otherwise, stays as strong.”

FDA Approvals and Filings

The Company recently received an approval from the U.S. Food and Drug Administration (“FDA”) for the Abbreviated New Drug Application (“ANDA”): Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%. The Company currently has a total of eighteen ANDAs awaiting FDA approval, including five tentative approvals.

Launch of Specialty Generic Deferiprone Tablets, 500mg in the U.S.

On September 28, 2020, Taro announced the launch of a new specialty generic, Deferiprone Tablets, the generic version of Ferriprox®. This drug product for orphan indication expands Taro’s capabilities to include specialty products.

Acquisition of Aquinox

On July 31, 2020, Taro Pharmaceuticals, Inc. completed the purchase of Aquinox Pharmaceuticals (Canada) Inc. (“Aquinox”), a wholly-owned subsidiary of Neoleukin Therapeutics, Inc., including intellectual property rights to various early stage molecules. Pursuant to the agreement, Taro acquired all issued and outstanding shares of Aquinox for $8.2 million.

Earnings Call (8:00 am EST, October 29, 2020)

As previously announced, the Company will host an earnings call at 8:00 am EST on Thursday, October 29, 2020, where senior management will discuss the Company’s performance and answer questions from participants. This call will be accessible through an audio dial-in and a web-cast. Audio conference participants can dial-in on the numbers below:

  • Participant Toll-Free Dial-In Number: +1 (844) 421-0601 ID: 3484939
  • Participant International Dial-In Number: +1 (716) 247-5800 ID: 3484939
  • Audio web-cast: Details are provided on our website, www.taro.com

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available on the Company’s website at www.taro.com.

The Company cautions that the foregoing financial information is presented on an unaudited basis and is subject to change.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

SAFE HARBOR STATEMENT

The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company. The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2021. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company’s financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(U.S. dollars in thousands, except share data)
 
Quarter Ended Six Months Ended
September 30, September 30,

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Sales, net

$

142,843

 

$

160,850

 

$

260,477

 

$

322,146

 

Cost of sales

 

61,255

 

 

59,247

 

 

113,943

 

 

118,819

 

Gross profit

 

81,588

 

 

101,603

 

 

146,534

 

 

203,327

 

 
Operating Expenses:
Research and development

 

16,552

 

 

15,539

 

 

29,484

 

 

28,982

 

Selling, marketing, general and administrative

 

24,074

 

 

23,652

 

 

46,323

 

 

43,370

 

Settlements and loss contingencies

 

 

 

(150

)

 

478,924

 

 

(150

)

Operating income (loss)

 

40,962

 

 

62,562

 

 

(408,197

)

 

131,125

 

 
Financial (income) expense, net:
Interest and other financial income

 

(5,678

)

 

(8,857

)

 

(12,988

)

 

(18,481

)

Foreign exchange (income) expense

 

(632

)

 

45

 

 

(829

)

 

(7,860

)

Other gain, net

 

1,380

 

 

1,082

 

 

1,929

 

 

1,676

 

Income (loss) before income taxes

 

48,652

 

 

72,456

 

 

(392,450

)

 

159,142

 

Tax expense

 

3,590

 

 

16,246

 

 

12,444

 

 

36,691

 

Net income (loss)

 

45,062

 

 

56,210

 

 

(404,894

)

 

122,451

 

Net (loss) income attributable to non-controlling interest

 

(70

)

 

32

 

 

(15,108

)

 

90

 

Net income (loss) attributable to Taro

$

45,132

 

$

56,178

 

$

(389,786

)

$

122,361

 

 
Net income (loss) per ordinary share attributable to Taro:
Basic and Diluted

$

1.18

 

$

1.46

 

$

(10.19

)

$

3.17

 

 
Weighted-average number of shares used to compute net income per share:
Basic and Diluted

 

38,258,337

 

 

38,539,056

 

 

38,258,337

 

 

38,539,056

 

 
May not foot due to rounding.  
TARO PHARMACEUTICAL INDUSTRIES LTD.
SUMMARY CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
 
September 30, March 31,

 

2020

 

 

2020

ASSETS (unaudited) (audited)
CURRENT ASSETS:
Cash and cash equivalents

$

498,796

 

$

513,354

Marketable securities

 

543,204

 

 

595,383

Accounts receivable and other:
Trade, net

 

231,670

 

 

235,221

Other receivables and prepaid expenses

 

44,947

 

 

35,567

Inventories

 

167,213

 

 

153,073

TOTAL CURRENT ASSETS

 

1,485,830

 

 

1,532,598

Marketable securities

 

476,800

 

 

459,639

Property, plant and equipment, net

 

207,923

 

 

209,961

Deferred income taxes

 

143,297

 

 

106,693

Other assets

 

32,258

 

 

32,361

TOTAL ASSETS

$

2,346,108

 

$

2,341,252

 
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables

$

39,967

 

$

28,858

Other current liabilities

 

547,349

 

 

193,873

TOTAL CURRENT LIABILITIES

 

587,316

 

 

222,731

Deferred taxes and other long-term liabilities

 

40,047

 

 

8,762

TOTAL LIABILITIES

 

627,363

 

 

231,493

 
Taro shareholders’ equity

 

1,727,957

 

 

2,103,864

Non-controlling interest

 

(9,212

)

 

5,895

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$

2,346,108

 

$

2,341,252

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(U.S. dollars in thousands)
 
Six Months Ended September 30,

 

2020

 

 

2019

 

Cash flows from operating activities:
Net (loss) income

$

(404,894

)

$

122,451

 

Adjustments required to reconcile net income to net cash provided by operating activities:
Depreciation and amortization

 

11,361

 

 

10,654

 

Change in derivative instruments, net

 

(942

)

 

(2,758

)

Effect of change in exchange rate on inter-company balances, marketable securities and bank deposits

 

(3,569

)

 

(6,210

)

Deferred income taxes, net

 

(39,591

)

 

302

 

Decrease (increase) in trade receivables, net

 

3,550

 

 

(9,556

)

Increase in inventories, net

 

(14,140

)

 

(360

)

(Decrease) increase in other receivables, income tax receivables, prepaid expenses and other

 

(8,451

)

 

22,184

 

Increase (decrease) in trade, income tax, accrued expenses and other payables

 

407,522

 

 

(12,139

)

Loss (income) from marketable securities, net

 

1,007

 

 

(1,210

)

Net cash (used in) provided by operating activities

 

(48,147

)

 

123,358

 

 
Cash flows from investing activities:
Purchase of plant, property & equipment, net

 

(8,953

)

 

(13,603

)

Investment in other intangible assets

 

(76

)

 

(45

)

Proceeds from (investment in) marketable securities, net

 

41,820

 

 

(116,494

)

Net cash provided by (used in) investing activities

 

32,791

 

 

(130,142

)

 
Cash flows from financing activities:
Net cash used in financing activities

 

 

 

 

 
Effect of exchange rate changes on cash and cash equivalents

 

798

 

 

 

Decrease in cash and cash equivalents

 

(14,558

)

 

(6,784

)

Cash and cash equivalents at beginning of period

 

513,354

 

 

567,451

 

Cash and cash equivalents at end of period

$

498,796

 

$

560,667

 

 
Cash Paid during the year for:
Income taxes

$

20,596

 

$

21,841

 

Cash Received during the year for:
Income taxes

$

4,093

 

$

6,964

 

Non-cash investing transactions:
Purchase of property, plant and equipment included in accounts payable

$

1,410

 

$

2,000

 

Non-cash financing transactions:
Purchase of intangible assets

$

 

$

1,000

 

Purchase (sale) of marketable securities

$

2,435

 

$

10,425

 

 

Contacts

Daphne Huang

VP, Chief Financial Officer

(914) 345-9000

[email protected]

William J. Coote

AVP, Treasurer and Investor Relations

(914) 345-9000

[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.